America's Drug Approval Paradox: Racing to Market, Failing at Access

A Kentucky teacher with chronic migraines gets a prescription for Nurtec. Her insurance denies it. A cancer patient in remission spends more time fighting coverage denials than she ever spent in chemotherapy. An asthmatic rationing a daily inhaler to once a week because the refill doesn't fit her budget. The FDA has approved 23 novel drugs so far this year—Lumvoa for thyroid eye disease, Uteбzi as the first oral carbapenem antibiotic, and an expanded approval for sacituzumab govitecan in triple-negative breast cancer—and the pharmaceutical industry is celebrating America's innovation leadership. But regulatory speed is a meaningless metric when working-class patients abandon medications at the pharmacy counter and drugs available in Canada and Europe never reach American patients at all.

On June 24, 2026, regulators cleared Tryngolza (olezarsen), the first and only treatment proven to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, demonstrating a 91 percent reduction in acute pancreatitis events. These approvals reflect ongoing innovation in endocrine, infectious disease, cancer, and diagnostic imaging—yet regulatory green lights only mark the beginning of the question: who actually gets to use these medicines?

Only 35 percent of first-year prescriptions for 99 novel medicines launched between 2020 and 2024 were filled. More than half remained unfilled by Year 4. The gap between approval and access isn't an accident. It's the intended result of a system where insurers profit from denials and pharmaceutical companies maximize revenue before worrying about who can afford treatment.

The First-to-Market Mirage

An HHS ASPE report analyzed 287 new prescription drugs launched between 2018 and 2022 across the United States and other OECD countries, finding that 57 percent were available in both the U.S. and comparison countries by the end of 2022. The U.S. was the fastest country to launch new drugs among 27 nations studied, especially for molecules with major incremental benefit or breakthrough designation. Eighty-five percent of new drugs sold here launched first in America or in the same quarter as abroad. The average lag after U.S. drug launch was approximately one year for other countries overall, with Japan following in about three quarters and Germany in about four quarters.

The industry uses this speed advantage to argue against price controls, claiming any constraint on profits will slow innovation. But the same data reveals what that argument conceals: 75 drugs—26 percent—were available in at least one comparison OECD country but not in the United States, while 48 drugs—17 percent—were available only in the U.S.

Examples of drugs approved abroad but not here include domperidone, approved in Canada, the EU, the UK, and Australia for nausea, and insulin icodec, the first once-weekly insulin approved in the EU, Canada, Australia, Japan, and China. Speed of regulatory approval doesn't guarantee availability, and other countries often deliver medicines the U.S. doesn't approve at all.

The Insurance Gatekeeping Business Model

Nearly two-thirds—65 percent—of prescriptions for newly launched drugs go unfilled in their first year on the market. Forty-nine percent are rejected by payers. Seventeen percent are abandoned by patients after approval due to cost.

These aren't bureaucratic failures. They're the core business model. Insurers and their Pharmacy Benefit Manager intermediaries make money by saying no.

Nearly 47 percent of new branded medicine attempts under Medicare Part D were initially denied in 2025, with rejection rates rising 10 percentage points since 2021. Seventy percent of patients seeking branded medicines through commercial insurance were initially denied coverage, and 54 percent of commercially insured adults reported their health insurance plan no longer covered medications for chronic or rare conditions in 2025.

One patient with a chronic condition described the manufactured crisis: "My insurance denied my medication. … And it's just really scary. If I get bad, I'm in the hospital for 10 days minimum more expensive treatment. So, it's just hard that they don't take my doctor's word for it."

Prior authorization is designed as a barrier to medication access and can delay approval for days, weeks, or months. Ninety-seven percent of medical practices reported their patients experienced care delays or denials due to increased prior authorization requirements in a 2023 survey. Thirty-nine percent of patients denied coverage experienced a delay of one month or more, with 7 percent facing delays of six months or longer. Ninety-two percent of patients who were denied coverage reported adverse effects, primarily on mental health—36 percent—and physical health—32 percent.

Ninety-four percent of physicians say prior authorization delays access to necessary care, and 33 percent report it has caused serious harm to patients. Up to one-third of patients never pick up approved medications after prior authorization hurdles, even when physicians successfully fight for approval. Eighty-two percent of prior authorization appeals succeed when proper documentation is provided, suggesting that many initial denials serve as administrative barriers rather than evidence-based medical necessity determinations.

The American Medical Association warns: "When prior authorization turns a physician's prescription into merely a recommendation, insurers are making medical decisions without ever seeing the patient."

The Affordability Weapon

One out of four prescriptions is abandoned at the pharmacy due to affordability. Patients abandoned 94 million prescriptions as out-of-pocket costs for retail brands rose by $949 million from 2021 to 2022. Nearly 20 percent of patients left the pharmacy without their prescription after learning of unexpected costs.

One patient facing coverage denial explained: "The insurance stopped covering it altogether, so that went way up… I had to stop that for quite some time until I could work that into the budget."

An asthma patient described rationing care: "I use [asthma medication] once a week when I'm supposed to use it daily because I just cannot cover that 'cause it's too much and I don't have a copay card or anything to offset the cost. And so, what that leaves me with is constant worry that I'm going to have a breathing issue."

The price gap isn't a market accident. It's the result of political choices that prioritize pharmaceutical profits over patient survival. The U.S. averages prescription drug prices 2.78 times higher than 33 other nations, with brand-named drugs averaging 4.22 times higher.

Uninsured adults—22.9 percent—are more than three times as likely as those with private insurance—6.5 percent—to not take medications as prescribed due to cost. Adults with disabilities—20.0 percent—are nearly three times more likely than those without disabilities—7.1 percent—to not take medication as prescribed due to cost.

High prescription drug prices and insurance design features—deductibles, copays, formulary changes, prior authorization, and step therapy—are major barriers to medication access even for people who are insured. Pharmacy Benefit Managers are the principal purchasers of drugs for 266 million Americans, yet their lack of transparency keeps negotiated fees and rebate shares confidential.

The International Proof of Concept

Other high-income countries with universal healthcare systems and price negotiation frameworks still receive innovative medicines—just with more equitable distribution and without the coverage denials and cost-driven abandonment plaguing U.S. patients. The fact that 26 percent of new drugs were available in at least one comparison OECD country but not in the United States demonstrates that the U.S. regulatory approach doesn't guarantee American patients access to all beneficial therapies. The international data exposes a false choice: countries don't have to choose between innovation speed and equitable access.

First to Market, Last to Benefit

A cancer patient summarized the burden: "My energy to fight my cancer was diverted to finding ways to pay for my prescriptions."

A teacher with a chronic condition explained: "The high cost of Nurtec makes it hard to consistently afford the medication I need to stay present in the classroom and maintain my quality of life. It shouldn't be this difficult for someone with a chronic condition to access a medication that works."

Patients For Affordable Drugs summarizes the paradox: "Drugs don't work if people can't afford them."

When working-class Americans, the uninsured, and people with disabilities face access rates three times worse than the privately insured, the first-to-market metric measures speed to market launch, not speed to patient benefit—and regulatory speed becomes irrelevant to equity.

Policy Battles and Profit Defense

CMS proposed a new rule in 2026 to require electronic prior authorization for drugs, set fast decision timelines—24-hour decisions for urgent requests and 72-hour decisions for standard requests—and mandate detailed denial reasons to reduce access barriers across Medicare, Medicaid, CHIP, and ACA marketplace plans, with compliance beginning October 1, 2027.

Medicare negotiated drug prices are expected to save approximately $1.5 billion in 2026, with about 19 million Medicare patients saving approximately $400 per year in 2025. The White House outlined a Most-Favored-Nation drug pricing framework that leverages cross-country sales and launch data, including implementation of the Medicare GLP-1 Bridge starting July 1, 2026, to expand access to anti-obesity GLP-1 drugs while controlling costs.

HHS is planning reforms to entice drug developers to initiate early-stage clinical trials in the U.S. rather than overseas, aiming to accelerate domestic access to new therapies. The Association for Accessible Medicines identified outdated FDA requirements, patent abuses creating "patent thickets," and flawed Medicare/PBM policies as key barriers delaying approval of affordable generics and biosimilars in 2025–2026.

Policy solutions exist—price negotiation, prior authorization reform, PBM transparency requirements, generic and biosimilar access expansion—but they require political will to prioritize patient access over pharmaceutical profit margins. Without distributive accountability—mechanisms that measure not just approval speed but fill rates, denial rates, and equity of access across income and insurance status—the FDA's 2026 approval wave will remain a headline for industry press releases rather than a breakthrough for public health. The cross-national data from the ASPE report makes clear that the U.S. can maintain its innovation ecosystem while ensuring equitable distribution—other countries prove it's possible, and American patients deserve the same.